Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. difficile Infections Published in The Lancet Infectious Diseases

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...
The Morning Journal

Charlotte Gardiner receives Dr. Alex and Maria Zolli Living Angel Award

Charlotte Gardiner, Ph.D., is a living angel. Gardener, president of Mercy Health — St. Joseph Warren Hospital since 2022, was recognized March 7 as the recipient of the Dr. Alex and Maria ...
Le Lézard

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile ...

Acurx Pharmaceuticals, Inc.  ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced ...

Acurx Pharmaceuticals, Inc.: Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...